July 21, 2022

Group co-chairs Peter O’Dwyer and Mitch Schnall commend the selection of Monica Bertagnolli as the next NCI director

July 15, 2022

Ongoing Smoke Free Support Study 2.0 featured in BioMed Central’s Public Health Journal

July 2, 2022

What is ECOG-ACRIN EA2142? And why should you care?

June 28, 2022

The Summer 2022 advocacy blog, Considering Clinical Trials, is now available

June 22, 2022

FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH

June 20, 2022

TMIST breast cancer trial looks to recruit underserved communities

June 8, 2022

Dr. Abhishek Tripathi discusses the 8-year survival outcomes from the CHAARTED trial for patients with advanced prostate cancer

June 7, 2022

Pancreatic neuroendocrine tumors: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

June 7, 2022

E2108 evidence informs a discussion on systemic therapy vs surgery for de novo stage IV breast cancer

ECOG-ACRIN Cancer Research Group